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Abstract  
 
Background:  The Global Registry on Long-Term Oral Antithrombotic Treatment in 
Patients with Atrial Fibrillation (GLORIA-AF) was designed to provide prospectively 
collected information on patients with newly diagnosed non-valvular atrial fibrillation at 
risk of stroke, with the aim of addressing treatment patterns and questions of 
effectiveness and safety.   
Methods and Results: In this predefined analysis from GLORIA-AF, the baseline 
characteristics and initial antithrombotic management of the first 10 000 patients in Phase 
II of this large Registry Program are presented. 
Overall, 32.3% of patients received VKAs and 47.7% received NOACs, whilst 12.3% 
received antiplatelet treatment and 7.6 % did not receive any antithrombotic treatment. 
Amongst patients with CHA2DS2VASc score ≥2, 6.7 % received no antithrombotic 
treatment and 10.0% received aspirin.  
In Europe, treatment with dabigatran was as common as treatment with VKAs (38.8% 
and 37.8%, respectively). More than half of the patients were treated with NOACs 
(52.4%), whilst antiplatelet treatment was given to 5.7 %, and 4.1% did not receive any 
antithrombotic treatment. In North America, treatment with dabigatran (25.0%) was as 
common as with VKAs (26.1%), but overall NOAC use was more common (52.1%) than 
with VKAs (26.1%); however, 14.1% received antiplatelet treatment, while 7.6 % 
received no antithrombotic treatment. In Asia, treatment with VKAs (31.9%) was more 
prevalent than NOACs (25.5 %), but antiplatelet treatment was given to 25.8% and 
16.9% did not receive any antithrombotic treatment. In Asia, only 60.7% of patients with 
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high stroke risk received oral anticoagulants (OACs).  Paroxysmal atrial fibrillation and 
minimally symptomatic (or asymptomatic) patients were often undertreated with OACs. 
Conclusion:  In this analysis, OAC use was high in Europe and North America, with 
overall NOAC use higher than VKA use. A considerable percentage of high-risk patients 
in North America still received antiplatelet treatment or were untreated, whilst Asian 
patients had a high proportion of aspirin use and non-treatment.  
 
Keywords: atrial fibrillation, registry, stroke, anticoagulation 
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Introduction 
 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, which confers a 
high risk of ischemic stroke and systemic thromboembolism.  Adjusted-dose warfarin 
reduces the risk of stroke or systemic embolism by 64% and all-cause mortality by 26% 
when compared with placebo(1). In contrast, aspirin reduces stroke occurrence by an 
estimated 19%, with no reduction in mortality(1).  
 
Although Vitamin K antagonists (VKAs) are very effective in reducing stroke risk, there 
are many limitations with their use(2). VKAs have many interactions with food and drugs, 
a narrow therapeutic window, delayed onset and offset of action, and need for frequent 
coagulation monitoring and drug dose adjustment(2).  Also, the efficacy and safety of 
VKAs is dependent on the quality of anticoagulation control(2), as reflected by the time 
in therapeutic range (TTR)(3, 4).  Guidelines currently recommend a TTR of >70%(5).    
Unsurprisingly, VKAs were still much underused in patients with atrial fibrillation who 
were at high risk of stroke, and instead, many patients with atrial fibrillation are 
prescribed aspirin or no antithrombotic therapy(6, 7).  
 
Now that various non-VKA oral anticoagulants (NOACs), including dabigatran etexilate 
(dabigatran), rivaroxaban, apixaban, and edoxaban have been approved for stroke 
prevention in patients with non-valvular atrial fibrillation in many countries, the 
antithrombotic treatment patterns of practice have changed. It is therefore essential that 
additional collection of data from routine clinical practice be carried out to understand 
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these antithrombotic patterns and to further characterize the broad spectrum of 
comorbidities and other medication use. 
 
The Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with 
Atrial Fibrillation (GLORIA-AF) was designed to provide prospectively collected 
information on patients with newly diagnosed non-valvular atrial fibrillation at risk of 
stroke, with the aim of addressing treatment patterns and questions of effectiveness and 
safety. The design and objectives of GLORIA-AF have been previously published(8), 
and Phase II of this Registry Program was started shortly after the approval of the first 
NOAC in the respective country. This design allowed the systematic collection of data on 
antithrombotic treatment of newly diagnosed non-valvular atrial fibrillation patients, 
especially in the first years after NOAC availability. 
 
In the present predefined analysis from GLORIA-AF, the baseline characteristics and 
initial antithrombotic management of the first 10 000 patients in Phase II of this large 
Registry Program are presented. 
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Methods 
GLORIA-AF is an ongoing international disease registry program in newly diagnosed 
non-valvular atrial fibrillation patients, run in three separate phases(8).   Phase I, 
conducted before the approval of dabigatran, used a cross-sectional approach. During 
Phase II of GLORIA-AF, which has been started per country following the approval of 
dabigatran, cross-sectional data are collected. In addition, patients initiated on dabigatran 
will have 2-year follow-up data collected. Phase III will study the effectiveness and 
safety of dabigatran compared with VKA for stroke prevention in patients with non-
valvular atrial fibrillation, and will commence once baseline patient characteristics are 
similar enough to conduct comparisons. This will be determined by sufficiently 
overlapping ranges of the respective propensity score distributions for patients on VKA 
and dabigatran in the Phase II analysis. 
 
This pre-specified interim analysis of Phase II describes baseline data from the first 
10000 patients included in GLORIA-AF Phase II from all five defined geographical 
regions (Figure 1). 
 
Patients  
Consecutive patients aged ≥18 years with newly diagnosed non-valvular atrial fibrillation 
diagnosed at a maximum of 3 months before their baseline visit and a CHA2DS2VASc 
(congestive heart failure, hypertension, age ≥ 75, diabetes, stroke, vascular disease, age 
65–74, sex category) score ≥1 were included. Stroke and bleeding risk were assessed 
based on the CHA2DS2VASc and HAS-BLED (hypertension, abnormal renal and liver 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
7 
 
function , stroke, bleeding, labile international normalized ratios, elderly , drugs or 
alcohol) scores, respectively(9, 10).  Patients were recruited from a variety of outpatient 
settings, including university hospitals, specialist offices, and community hospitals. 
 
Patients were excluded for the following reasons: mechanical heart valves or valve 
disease expected to require valve replacement during the course of the registry, >60 days 
of VKA treatment in their lifetime for any indication, atrial fibrillation with a generally 
reversible cause, life expectancy <1 year, or another indication than atrial fibrillation for 
VKAs. At the baseline visit, in a standard electronic case report form (e-CRF), clinical 
and demographic characteristics were recorded, as was the type of atrial fibrillation and 
management approach. The definition of drug treatment groups used for the analysis are 
shown in Appendix 1.  
 
Study quality assurance 
Data were collected in an electronic case report form. Data quality was monitored 
electronically, as well as through periodic manual medical and data quality reviews, on-
site monitoring, and audits. Investigators were asked to consecutively enrol all eligible 
patients in order to minimize selection bias at the patient level. The design of the registry 
as well as the scientific oversight of all phases of the program was supported by an 
academic steering committee. 
 
Statistics 
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Baseline data were summarized descriptively, displaying mean and standard deviation 
and/or median and interquartile ranges for continuous variables. Categorical variables 
were expressed as absolute frequencies and percentages. All analyses were descriptive in 
nature. All statistical analyses were performed using SAS software version 9.2. 
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Results 
From November 2011 (date of first patient in) until February 2014 (date of last patient 
entered in this data cut for the interim analysis), 10 871 patients from 736 centres were 
enrolled in Phase II of the Registry Program. Of the enrolled patients, 10 675 were 
eligible for inclusion in the analysis from the following regions: Asia (n = 1957), Europe 
(n = 4703), North America (n = 3415), Latin America (n = 476), and Africa/Middle East 
(n = 124). The country participation per defined region is shown in Figure 1. 
 
The participating care settings were specialist offices (33.4%), university hospitals 
(30.8%), community hospitals (12.6%), primary care (11.4 %), and other (11.7%). The 
main prescribing physicians were cardiologists (91.7%). General practitioners, 
geriatricians, neurologists, and internists enrolled the remaining patients. 
The median age of the study population was 71 years.  Many patients had one or more 
comorbidities, including hypertension, coronary artery disease, myocardial infarction, 
and previous stroke. Further patient demographics and medical history are summarized in 
Table 1. 
 
Paroxysmal atrial fibrillation was present in 54.5% of patients, while 34.9% had 
persistent atrial fibrillation and 10.6 % had permanent atrial fibrillation. Atrial fibrillation 
was symptomatic in 26.8%, minimally symptomatic in 41.7%, and asymptomatic in 
31.4% (Figure 2). 
 
Stroke and Bleeding Risk Scores 
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More than half of the patients enrolled had a CHADS2 score ≥2 (57%), and 85.5% had 
CHA2DS2VASc score ≥2. The mean CHADS2 score was 1.9 (SD 1.1) and the mean 
CHA2DS2VASc score was 3.2 (SD 1.5) (Table 1).  Most (79.3%) patients had HAS-
BLED bleeding risk scores of <3. The mean HAS-BLED score was 1.4 (SD 0.9) (Table 1). 
 
Selection of Antithrombotic Therapy 
Overall, 32.3% of patients (n = 3449) received VKAs, while 32.2% (n = 3439) received 
dabigatran. When all NOACs were analysed together, more patients received NOACs 
(47.7%) than VKAs. Antiplatelet treatment was given to 12.3% of patients overall, while 
7.6 % of patients did not receive any antithrombotic treatment (Figure 3). 
When assessing treatment pattern per stroke risk scores, in patients with a 
CHA2DS2VASc score of 1, 13.2 % received no antithrombotic treatment and 20.3% 
received antiplatelet treatment. Amongst patients with higher stroke risk (CHA2DS2VASc 
score ≥2), corresponding figures were 6.7 % and 10.0 %, respectively (Figure 3). 
  
Selection of Antithrombotic Therapy by Region 
For Europe, treatment with dabigatran was as common as treatment with VKAs, with 
usage by 38.8% and 37.8% of patients, respectively. When all NOACs were considered 
together, more than half of the patients were treated with NOACs (52.4%). Antiplatelet 
treatment was given to 5.7 % of patients, while 4.1% of patients did not receive any 
antithrombotic treatment (Figure 4). 
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For North America, treatment with dabigatran (25.0%) was as common as with VKAs 
(26.1%), but considered altogether, treatment with NOACs was more common (52.1%) 
than with VKAs (26.1%). A total of 14.1% of patients received antiplatelet treatment, 
while 7.6 % received no antithrombotic treatment. In Asia, treatment with VKAs (31.9%) 
was more prevalent than with dabigatran or other NOACs (25.5 %). Antiplatelet 
treatment was given to 25.8% of patients, while 16.9% of patients did not receive any 
antithrombotic treatment (Figure 4). 
 
When the regional treatment patterns are assessed based on the CHA2DS2-VASc score in 
patients with a high stroke risk (CHA2DS2-VASc Score ≥2), the percentage of VKA and 
NOAC treatments increased (Figure 5). For example, in Europe, 91.1% of patients with 
CHA2DS2-VASc Score ≥2 were treated with VKAs or NOACs. In North America and 
Latin America, these numbers were 80.7% and 86.1%, respectively. In Asia, only 60.7% 
of patients with high stroke risk received OACs (Figure 5). 
 
Selection of Antithrombotic Therapy per Type of atrial fibrillation and per 
Symptoms 
Table 2 presents a summary of atrial fibrillation type and symptom category by 
antithrombotic treatment choice for stroke. Although patients having paroxysmal atrial 
fibrillation composed the largest proportion within each of the treatment cohorts (54.5%), 
aspirin (72.6% of paroxysmal atrial fibrillation patients) and no treatment (“none”) 
groups (62.8% of paroxysmal atrial fibrillation patients) comprised larger percentages 
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than the VKA (48.3%) and NOAC (dabigatran 51.3%, rivaroxaban 56.2%, apixaban 
56.1%) treatment groups. 
Although patients with permanent atrial fibrillation composed the smallest proportion of 
patients within each individual treatment group, VKA and NOAC use were more 
prevalent. Permanent atrial fibrillation patients were older on average, and included a 
larger proportion of patients with high CHA2DS2-VASc stroke risk score compared with 
the other atrial fibrillation types [full data not shown]. 
 
Approximately two-thirds of the patients were symptomatic or minimally symptomatic 
(28.8% and 41.7%, respectively), while the remaining patients were asymptomatic 
(31.4%). While VKA and aspirin treatment did not differ per symptom category, some 
variations in treatment choice by atrial fibrillation symptom category were observed for 
dabigatran (symptomatic 32.9%, minimally symptomatic 34.7%, and asymptomatic 
28.4%). The percentage of patients who did not receive any treatment was higher in 
asymptomatic and minimally symptomatic patients (8.4% and 8.1%, respectively) as 
compared with the symptomatic patients (5.9%). 
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Discussion 
In this pre-specified interim analysis of the first cohort of more than 10 000 patients 
entered into Phase II of the GLORIA-AF Registry, our principal findings are as follows: 
(i) OAC use was high in Europe and North America, with overall NOAC use higher than 
VKA use; (ii) a considerable percentage of high-risk patients in North America still 
received antiplatelet treatment or were untreated; (iii) Asian patients had a high 
proportion of aspirin use and non-treatment despite atrial fibrillation subjects having ≥1 
stroke risk factors; (iv) paroxysmal atrial fibrillation and minimally symptomatic (or 
asymptomatic) patients were often undertreated with OAC; and (iv) aspirin was 
commonly used in patients at high risk of bleeding patients. 
 
Overall, treatment with VKAs (32.3%) and dabigatran (32.2%) were equally common, 
followed by rivaroxaban (12 %) and antiplatelet treatment (12.3%). When all NOACs 
were taken together as a group, more patients received NOACs (47.7%) than VKAs 
(32.3%). 
 
The results of this Phase II analysis reflect the changing field of antithrombotic 
management in patients with non-valvular atrial fibrillation. First, when compared with 
earlier registry data(11), many more patients were prescribed antithrombotic treatment. In 
the present analysis, only 7.6% of patients with an indication for anticoagulation did not 
receive such.  In contrast, the corresponding number was 30% in the EuroHeart survey 
over the period 2003-2004.12 Second, NOACs are now more commonly prescribed than 
VKAs amongst anticoagulated patients, signaling the extent to which clinical practice has 
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changed after the introduction of NOACs. Third, antiplatelet treatment was still 
prescribed in 11.5% of patients, although regional differences are apparent. 
When subdivided by region, important differences of treatment patterns were observed. 
In Europe, 52.4% of patients received any NOAC versus 37.8% VKA, only 5.7% 
received Aspirin or another antiplatelet, and 4.1% received no antithrombotic treatment at 
all.  
In North America twice as many patients received any NOAC (57.5%) compared with 
VKA (26.1%). When comparing the two regions many more patients in North America 
received Aspirin or another antiplatelet drug (14.1%) than those in Europe. Finally, in 
Asia, many patients received antiplatelet treatment (25.7%), while VKAs were more 
prescribed than any NOAC. 
 
There are important reasons for the higher number of patients being treated with Aspirin 
in North America and Asia as compared with Europe. In North America, this high 
number reflects the current guidelines, in which aspirin is still mentioned as an alternative 
to VKAs or NOACs, irrespective of stroke risky (12). In the latest European guidelines, 
aspirin is not recommended, although aspirin-clopidogrel (or, less effectively, aspirin) 
may be considered only after any form of OAC is refused(5).    
 
In Asia, VKAs are less commonly given to patients with non-valvular atrial fibrillation, 
probably because of the perceived risk of bleeding during treatment(13). VKA-related 
intracranial bleeding is also higher in Asian patients(13, 14).  Second, many Asian 
patients lack access to good control for VKA therapy and therefore do not receive VKA 
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treatment(13); and even where VKA is used, the quality of anticoagulation control (as 
reflected by time in therapeutic range, TTR) may be suboptimal – indeed, TTR is closely 
related to thromboembolism and bleeding on warfarin(15).  Nonetheless, NOACs may be 
the better option for Asians, given that Asian patients with atrial fibrillation have higher 
stroke and bleeding rates on warfarin, compared with non-Asians(16).  Aspirin use is also 
common in Asia, but recent studies show that aspirin is neither safe nor effective for 
stroke prevention in Asians(17).  In a recent analysis of Chinese patients with atrial 
fibrillation, the benefits of warfarin therapy for stroke prevention and intracranial 
haemorrhage risk were closely dependent on the quality of anticoagulation, as reflected 
by TTRs(18).  Even at the top TTR quartile, warfarin was associated with a higher stroke 
and intracranial haemorrhage risk than dabigatran(18). Also, NOACs are not reimbursed 
in many Asian countries.   
Among the newly diagnosed non-valvular- atrial fibrillation patients there were 
predominantly patients with paroxysmal and permanent atrial fibrillation included, while 
the overall majority of patients (73.1%) were either asymptomatic or had minimal 
symptoms. This distribution reflects the fact that we included patients early in their 
disease, but prognosis with respect to the occurrence of ischemic stroke and mortality in 
asymptomatic patients may be even worse than in symptomatic patients(19, 20). 
 
Other international registries have also reported data on treatment patterns over the recent 
years. The GARFIELD Registry has reported treatment patterns in patients with newly 
diagnosed atrial fibrillation over the period 2009-2011(21). The median age, type of atrial 
fibrillation, and mean CHADS and CHA2DS2VASc score in that registry were similar to 
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those patients in the present registry. In GARFIELD, patients with CHADS2 scores of 0 
were included as well, but the registry contained no patients from the United States. 
Overall, only 4.5% of patients received NOACs, 26.5% received aspirin, and 40.7% of 
patients with a CHA2DS2VASc score of ≥2 received no antithrombotic treatment(21).  
 
The EORP-AF registry amongst European cardiologists showed that in more than 3000 
patients who were enrolled from February 2012 to March 2013, oral anticoagulants were 
used in 80%, most often VKAs (71.6%), with NOACs being used in 8.4%(22). Other 
antithrombotics (mostly antiplatelet therapy, especially aspirin) were still used in one-
third of the patients. In EORP-AF, the mean CHA2DS2VASc score was 3.2 and the mean 
HAS-BLED score was 1.4.  The lower use of NOACs in the EORP registry may reflect 
inclusion of patients up to 2013, while in GLORIA-AF, patients were entered until 2014. 
 
Limitations 
This study includes patients at enrolling sites and consequently treatment patterns could 
be influenced by site selection. Two-thirds of study centres were either university 
hospitals or community hospitals, which may have increased the prevalence of patients 
treated with either dabigatran or other NOACs. However, we tried to overcome 
challenges stemming from arbitrary patient selection by asking sites to include 
consecutive patients from randomly selected representative practices.  For operational 
reasons, at the time point of this interim analysis only a limited number of patients was 
included in the registry program from certain areas, including Africa, the Middle East, 
and Latin America. The final analysis of the Phase II baseline data will allow an 
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assessment of the included regions in representative manner. In addition, the follow-up of 
GLORIA-AF Phase II will provide further information on the outcome of the patients as 
a function of therapies prescribed in daily clinical practice.   
 
Conclusion 
This interim analysis of the baseline Phase II data of the GLORIA-AF Registry 
demonstrates that the introduction of the NOACs into clinical practice have significantly 
influenced treatment patterns, especially in Europe and North America. In these areas of 
the world, NOACs were proportionally more commonly prescribed than VKAs. 
Furthermore, high proportions of patients at high risk of stroke still remain untreated or 
undertreated (e.g. those receiving aspirin); this is most pronounced in Asia but also true 
in North America and Europe. 
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FIGURE LEGENDS 
 
Figure 1 Definition of Geographical Regions and Country Participation in GLORIA-AF. 
Figure 2 AF Types and Symptom Categories (all Regions). 
Figure 3 Antithrombotic Treatment at Baseline overall and by Stroke Risk (all Regions).  
Figure 4 Antithrombotic Treatment at Baseline by Region.  
Figure 5 Antithrombotic Treatment at Baseline by Stroke Risk and Region. 
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Table 1: Patient demographics for overall population (N = 10 675) 
 Total 
Age, median (IQR), years 71.0 (64.0, 78.0) 
Female, n (%) 4862 (45.5) 
BMI, median (IQR), kg/m2 27.80 (24.70, 31.80) 
Creatinine clearance, median (IQR), mL/min 75.2 (56.2, 98.9)* 
Medical history, n (%)   
Previous stroke 999 (9.4) 
Myocardial infarction  1116 (10.5) 
Coronary artery disease 2195 (20.6) 
Congestive heart failure 2530 (23.7) 
Hypertension 7993 (74.9) 
Diabetes mellitus 2454 (23.0) 
Prior bleed 608 (5.7) 
CHADS2 score class, n (%)  
Low (score = 0) 896 (8.4) 
Moderate (score = 1) 3694 (34.6) 
High (score ≥ 2) 6081 (57.0) 
Missing 4 (0.0) 
CHA2DS2-VASc score class, n (%)  
Score = 1 1551 (14.5) 
Score ≥ 2 9123 (85.5) 
Missing 1 (0.0) 
HAS-BLED score  
Mean (SD) score 1.4 (0.9) 
Missing, n (%)   1299 (12.2) 
HAS-BLED score class  
Low (score < 3), n (%)   8469 (79.3) 
High (score ≥ 3), n (%)   907 (8.5) 
  
BMI, body mass index; IQR, interquartile range; * missing data > 1.5% 
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CHADS2, congestive heart failure, hypertension, age ≥ 75, diabetes, stroke (doubled);  
CHA2DS2-VASc, congestive heart failure, hypertension, age ≥ 75 (doubled), diabetes,  
stroke (doubled), vascular disease, age 65–74, sex category (female). ASPIRIN, 
acetylsalicylic acid; HAS-BLED, hypertension, abnormal renal and liver function (1 
point each), stroke, bleeding, labile international normalized ratios, elderly (e.g. age > 65 
years), drugs or alcohol (1 point each) (where “drugs/alcohol” refers to concomitant use 
of drugs such as antiplatelet agents, non-steroidal anti-inflammatory drugs drugs, or 
alcohol abuse etc.); SD, standard deviation; VKA, vitamin K antagonist. 
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Table 2:  Summary of overall atrial fibrillation type and category by 
antithrombotic treatment for stroke prevention 
 
 DE VKA Riva Apix ASA None Total 
All eligible, N 3439 3449 1282 369 1225 814 10 675 
AF category, n (%) 
  Symptomatic 942 
(27.4) 
942 
(27.3) 
349 
(27.2) 
92 
(24.9) 
337 
(27.5) 
168 
(20.6) 
2866  
(26.8) 
  Minimally   
      
symptomatic 
1544 
(44.9) 
1407 
(40.8) 
444 
(34.6) 
131 
(35.5) 
530 
(43.3) 
362 
(44.5) 
4454  
(41.7) 
  Asymptomatic 953 
(27.7) 
1099 
(31.9) 
489 
(38.1) 
146 
(39.6) 
358 
(29.2) 
283 
(34.8) 
3353  
(31.4) 
  Missing 0  
(0.0) 
1  
(0.0) 
0  
(0.0) 
0  
(0.0) 
0  
(0.0) 
1  
(0.1) 
2  
(0.0) 
Type of AF, n (%) 
  Paroxysmal 1764 
(51.3) 
1667 
(48.3) 
721 
(56.2) 
207 
(56.1) 
889 
(72.6) 
511 
(62.8) 
5818  
(54.5) 
  Persistent 1237 
(36.0) 
1348 
(39.1) 
441 
(34.4) 
123 
(33.3) 
281 
(22.9) 
257 
(31.6) 
3724  
(34.9) 
  Permanent 438 
(12.7) 
432 
(12.5) 
120  
(9.4) 
39  
(10.6) 
55  
(4.5) 
45  
(5.5) 
1130  
(10.6) 
  Missing 0  
(0.0) 
2  
(0.1) 
0  
(0.0) 
0  
(0.0) 
0  
(0.0) 
1  
(0.1) 
3  
(0.0) 
AF, atrial fibrillation; Apix = apixaban; ASA, acetylsalicyclic acid; DE, dabigatran etexilate; 
Riva, rivaroxaban; SD, standard deviation; VKA, vitamin K antagonist. 
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Figure 1 
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Figure 2 
 
AF, atrial fibrillation. 
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Figure 3 
 
*Other includes antiplatelets other than Aspirin.  Scores refer to CHA2DS2-VASc score, which was missing for one patient.
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Figure 4 
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Figure 5 
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Appendix 1: 
Definition of Treatment Groups 
Name Definition 
Dabigatran Patients with DE +/- other antithrombotics, 
excluding patients with DE + (other NOAC, VKA) 
VKA Patients with VKA +/- other antithrombotics, 
excluding patients with VKA + {(NOAC}) 
Rivaroxaban Patients with Rivaroxaban +/- other 
antithrombotics, excluding patients with 
Rivaroxaban + {(other NOAC, VKA}) 
Apixaban Patients with Apixaban +/- other antithrombotics, 
excluding patients with Apixaban + {(other 
NOAC, VKA}) 
Aspirin Patients with Aspirin +/- other antithrombotics, 
excluding patients with Aspirin +/- {(NOAC, 
VKA}) 
None Patients without any antithrombotic treatment 
Total All patients, irrespective of treatment 
  
Dabigatran, dabigatran etexilate; Aspirin, acetylsalicylic acid; VKA, vitamin K 
antagonist 
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Clinical significance 
 
• In this global registry of patients with atrial fibrillation, oral anticoagulation 
use was high in Europe, whilst antiplatelet treatment was given to 5.7 %, and 
no antithrombotic therapy in 4.1%.  
• In North America, overall NOAC use was more common than with warfarin; 
however, 14.1% received antiplatelet treatment, and 7.6 % received no 
antithrombotic treatment.  
• In Asia, there was a high proportion of aspirin use and non-treatment amongst 
AF patients.  
 
